These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 17383435

  • 1. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS, Huo D.
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract] [Full Text] [Related]

  • 2. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with infliximab and immunomodulators: is the glass half empty?
    Deshpande AR, Abreu MT.
    Gastroenterology; 2008 Jun; 134(7):2161-3. PubMed ID: 18482585
    [No Abstract] [Full Text] [Related]

  • 4. Maintenance infliximab infusions forever?
    Lee SD, Surawicz CM.
    Am J Gastroenterol; 2002 Nov; 97(11):2917-8. PubMed ID: 12425570
    [No Abstract] [Full Text] [Related]

  • 5. [Indications and results of infliximab in Crohn's disease].
    Karoui S, Boubaker J, Filali A.
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [Abstract] [Full Text] [Related]

  • 6. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
    Lichtenstein GR.
    Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M, Karoui S, Meknini M, Matri S, Kallel L, Fekih M, Boubaker J, Filali A.
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [Abstract] [Full Text] [Related]

  • 8. Clinical challenges and images in GI. Oral lichenoid reaction in a patient with Crohn's disease receiving infliximab.
    Moss AC, Treister NS, Marsee DK, Cheifetz AS.
    Gastroenterology; 2007 Feb; 132(2):488, 829. PubMed ID: 17261307
    [No Abstract] [Full Text] [Related]

  • 9. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, Mañosa M, Esteve M, Merino O, Andreu M, Gutierrez A, Gomollón F, Cabriada JL, Montoro MA, Mendoza JL, Nos P, Gisbert JP.
    J Clin Gastroenterol; 2011 Feb; 45(2):113-8. PubMed ID: 21242747
    [Abstract] [Full Text] [Related]

  • 10. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M, Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives.
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [Abstract] [Full Text] [Related]

  • 11. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS.
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [Abstract] [Full Text] [Related]

  • 12. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
    Meier J, Sturm A.
    Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
    [No Abstract] [Full Text] [Related]

  • 13. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
    Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):851-8. PubMed ID: 16918890
    [Abstract] [Full Text] [Related]

  • 14. [Maintenance treatment by anti-tumor necrosis factor monoclonal antibody in Crohn's disease--long-term effects and safety].
    Matsui T.
    Nihon Shokakibyo Gakkai Zasshi; 2008 May 01; 105(5):649-58. PubMed ID: 18460853
    [No Abstract] [Full Text] [Related]

  • 15. [Better to start from top?].
    MMW Fortschr Med; 2005 Oct 20; 147(42):8. PubMed ID: 16281774
    [No Abstract] [Full Text] [Related]

  • 16. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
    Loftus EV.
    Am J Gastroenterol; 2005 Jul 20; 100(7):1435-8. PubMed ID: 15984960
    [No Abstract] [Full Text] [Related]

  • 17. Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question.
    Blonski W, Lichtenstein GR.
    Gastrointest Endosc; 2006 Mar 20; 63(3):493-6. PubMed ID: 16500403
    [No Abstract] [Full Text] [Related]

  • 18. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J.
    Ugeskr Laeger; 2008 Jun 09; 170(24):2152-6. PubMed ID: 18565302
    [Abstract] [Full Text] [Related]

  • 19. Induction of pustular lesions during infliximab therapy for Crohn's disease.
    Pérez-Pérez L, Caeiro JL, Fabeiro JM, Allegue F, Zulaica A.
    Acta Derm Venereol; 2008 Jun 09; 88(3):292-3. PubMed ID: 18480940
    [No Abstract] [Full Text] [Related]

  • 20. Guidelines for treatment with infliximab for Crohn's disease.
    Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G, Dutch Initiative on Crohn and Colitis (ICC).
    Neth J Med; 2006 Jun 09; 64(7):219-29. PubMed ID: 16929083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.